Key statistics
As of last trade Organon & Co (1OGN:MIL) traded at 18.40, -15.25% below its 52-week high of 21.71, set on Jul 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.40 |
---|---|
High | 18.40 |
Low | 18.40 |
Bid | 16.00 |
Offer | -- |
Previous close | 16.03 |
Average volume | 0.00 |
---|---|
Shares outstanding | 257.47m |
Free float | 257.03m |
P/E (TTM) | 4.66 |
Market cap | 4.67bn USD |
EPS (TTM) | 3.89 USD |
Annual div (ADY) | 1.02 EUR |
---|---|
Annual div yield (ADY) | 6.35% |
Div ex-date | Aug 14 2024 |
Div pay-date | Sep 12 2024 |
Data delayed at least 15 minutes, as of Aug 22 2024 08:47 BST.
More ▼
Press releases
- Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
- Organon Reports Results for the Second Quarter Ended June 30, 2024